Does Pre-Existing Chronic Obstructive Pulmonary Disease Increase the Risk of Checkpoint Inhibitor Pneumonitis in Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?
Erhöht eine vorbestehende chronisch obstruktive Lungenerkrankung (COPD) das Risiko einer Checkpoint-Inhibitor-Pneumonitis bei fortgeschrittenem/metastasiertem nicht-kleinzelligem Lungenkarzinom unter Immun-Checkpoint-Inhibitoren?
Current Oncology · 29.04.2025 · 32 (5) · 259
DOI: 10.3390/curroncol32050259 ↗Auf einen Blick
In einer retrospektiven Kohorte von 327 NSCLC-Patient:innen war COPD nicht statistisch mit einem erhöhten Risiko für eine Checkpoint-Inhibitor-Pneumonitis assoziiert. Es zeigte sich nur ein Trend.
Fragestellung
Ist COPD bei mit Immun-Checkpoint-Inhibitoren behandelten Patient:innen mit fortgeschrittenem/metastasiertem NSCLC mit einem höheren Risiko für CIP verbunden?
Methode
Retrospektive Kohortenstudie an einem Zentrum in Montreal (2014–2023); Analyse mit Mann–Whitney-U-Test, Fisher-Exact-Test und logistischer Regression.
Ergebnisse
327 Patient:innen unter ICIs; 23 hatten eine CIP. COPD: 11/87 (12,6 %) vs. 13/240 (5,5 %), p = 0,061. Kein Zusammenhang mit COPD-Schwere; einzig ECOG-Status war signifikant.
Einschränkungen
Single-Center-Studie; die Autor:innen fordern größere prospektive Studien zur Bestätigung.
Schlussfolgerung der Autor:innen
Die Autor:innen berichten, dass COPD nicht statistisch mit einem erhöhten CIP-Risiko assoziiert war. FEV1 und DLCO hatten bei COPD-Patient:innen keinen bedeutsamen Einfluss.
Kernaussagen
- COPD: 12,6 % CIP vs. 5,5 % ohne COPD
- Kein signifikanter Zusammenhang zwischen COPD und CIP
- Schlechter ECOG-Status war mit CIP assoziiert
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 29.04.2025. Verfasst von David Spillane und 6 weiteren Autor:innen. Beteiligte Einrichtung: Anna and Peter Brojde Lung Cancer Centre, Jewish General Hospital, Montreal, QC H3T 1E2, Canada. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Pulmonary Disease, Chronic Obstructive, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: COPD
Abstract (Originalsprache)
Objective
Immune checkpoint inhibitors (ICIs) are front-line treatment options for NSCLC. ICI therapy is associated with a risk of immune-related adverse events (irAEs). Checkpoint inhibitor pneumonitis (CIP) is a potentially life-threatening irAE. Previous studies have demonstrated that asthma and interstitial lung disease are associated with an increased risk of CIP. We sought to determine whether chronic obstructive pulmonary disease (COPD) is associated with CIP.
Methods
This retrospective study examines a cohort of ICI-treated NSCLC patients either with or without chemotherapy at the Anna and Peter Brojde Lung Cancer Centre, Jewish General Hospital in Montreal, Canada between 2014 and 2023. We explored associations between risk factors and CIP using the Mann–Whitney U test or Fisher’s exact test. Analysis of prognostic factors was performed using a logistic regression model. All statistical analyses were carried out using SPSS software, version 24.0 (SPSS, Chicago, IL, USA). p-values of 0.05 or less were considered significant.
Results
Of the 327 selected patients on ICIs, 23 experienced an acute respiratory deterioration that was attributed to CIP, 87/327(26.6%) patients had a pre-existing diagnosis of COPD, and 11/87 (12.6%) COPD patients experienced CIP compared to 13/240 (5.5%) non-COPD patients (p = 0.061). There was no statistical or clinically meaningful correlation between COPD severity and CIP. The only variable significantly associated with CIP was a poor ECOG performance status. Among ECOG 1 patients, 18/91 (19.8%) experienced CIP compared to 5/226 (2.2%) of those with an ECOG of 0. A multivariate assessment involving all 327 patients revealed no significant factors affecting CIP development.
Conclusions
Our single-institution study revealed that although there was a trend, the presence of COPD was not statistically associated with an increased risk of CIP. Additionally, neither FEV1 nor DLCO had a meaningful impact on the development of CIP in COPD patients. Given these findings, we emphasize the need for larger prospective studies to confirm these observations before drawing definitive clinical recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anna and Peter Brojde Lung Cancer Centre, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
- Department of Medicine, McGill University, Montreal, QC H3A 0C7, Canada.
- Anatomy & Cell Biology, Downtown Campus, McGill University, Montreal, QC H3A 0C7, Canada.
ORCID-Profile: Goulnar Kasymjanova, Diane Cruiziat, Jeremy Naimer
Zitieren
APA
Spillane, D., Pepe, C., Kasymjanova, G., Cruiziat, D., Cohen, S., Naimer, J., & Agulnik, J. (2025). Does Pre-Existing Chronic Obstructive Pulmonary Disease Increase the Risk of Checkpoint Inhibitor Pneumonitis in Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?. Current Oncology, 32(5), 259. https://doi.org/10.3390/curroncol32050259
Vancouver
Spillane D, Pepe C, Kasymjanova G, Cruiziat D, Cohen S, Naimer J, et al. Does Pre-Existing Chronic Obstructive Pulmonary Disease Increase the Risk of Checkpoint Inhibitor Pneumonitis in Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?. Current Oncology. 2025;32(5):259. doi:10.3390/curroncol32050259
BibTeX
@article{Spillane2025,
author = {Spillane, David and Pepe, Carmela and Kasymjanova, Goulnar and Cruiziat, Diane and Cohen, Sara and Naimer, Jeremy and Agulnik, Jason},
title = {Does Pre-Existing Chronic Obstructive Pulmonary Disease Increase the Risk of Checkpoint Inhibitor Pneumonitis in Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {5},
pages = {259},
doi = {10.3390/curroncol32050259}
}
EUVIMED